2d) but showed no activity on the second procaspase stepping-stone PC_SS2 (Extended Data Fig
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
It is produced by the liver and involved in many body processes
You only need to be physically located in a state where our licensed providers practice during your telehealth visit
Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption enhancer with fasting to achieve exposure, and it can be taken without water or food restrictions, according to Phase 1 pharmacokinetic data